{"id":50360,"date":"2025-12-10T22:35:55","date_gmt":"2025-12-10T14:35:55","guid":{"rendered":"https:\/\/flcube.com\/?p=50360"},"modified":"2025-12-10T22:35:56","modified_gmt":"2025-12-10T14:35:56","slug":"shandong-boan-licenses-us-rights-for-denosumab-biosimilars-to-nanjing-kingfriend-in-75-million-deal","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=50360","title":{"rendered":"Shandong Boan Licenses US Rights for Denosumab Biosimilars to Nanjing Kingfriend in $75 Million Deal"},"content":{"rendered":"\n

Shandong Boan Biotechnology Co., Ltd.<\/strong> (HKG: 6955<\/a>) has granted Nanjing King-friend Biochemical Pharmaceutical Co., Ltd.<\/strong> (SHA: 603707<\/a>) exclusive rights to commercialize two Denosumab biosimilar<\/strong> injections, BA6101<\/strong> and BA1102<\/strong>, in the United States. Genor BioTech<\/strong>, Kingfriend\u2019s biologics arm, will lead stateside sales and promotion.<\/p>\n\n\n\n

Transaction Structure<\/h2>\n\n\n\n
Component<\/th>Details<\/th><\/tr><\/thead>
Products Licensed<\/strong><\/td>BA6101 (Prolia\u00ae biosimilar) & BA1102 (Xgeva\u00ae biosimilar)<\/td><\/tr>
Territory<\/strong><\/td>United States only<\/td><\/tr>
Upfront Payment<\/strong><\/td>$15\u202fmillion (payable on contract execution)<\/td><\/tr>
Milestone Payments<\/strong><\/td>Up to $60\u202fmillion ($20\u202fM on first commercial sale, $40\u202fM on achieving $100\u202fM cumulative net sales)<\/td><\/tr>
Royalties<\/strong><\/td>Tiered 15\u201320% of annual net U.S. sales<\/td><\/tr>
Responsibilities<\/strong><\/td>Kingfriend\/Genor<\/strong>: Sales, marketing, distribution; Boan<\/strong>: MAH, commercial manufacturing, supply<\/td><\/tr>
Effective Date<\/strong><\/td>1\u202fJan\u202f2026 (pending FTC antitrust review)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Product Portfolio<\/h2>\n\n\n\n
Attribute<\/th>BA6101 (Prolia Biosimilar)<\/th>BA1102 (Xgeva Biosimilar)<\/th><\/tr><\/thead>
Reference Product<\/strong><\/td>Prolia\u00ae (Amgen)<\/td>Xgeva\u00ae (Amgen)<\/td><\/tr>
Indication<\/strong><\/td>Postmenopausal osteoporosis<\/td>Bone metastases, giant cell tumor<\/td><\/tr>
China Approval<\/strong><\/td>2022 (commercial launch Q2\u202f2023)<\/td>2024 (launch pending)<\/td><\/tr>
US Filing Status<\/strong><\/td>BLA submission planned H2\u202f2026<\/td>BLA submission planned H1\u202f2027<\/td><\/tr>
Peak US Sales Forecast<\/strong><\/td>$120\u202fmillion (2029)<\/td>$85\u202fmillion (2030)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

US Market Opportunity<\/h2>\n\n\n\n

The U.S. Denosumab<\/strong> market exceeds $4.5\u202fbillion<\/strong> annually (Prolia $3.2\u202fB, Xgeva $1.3\u202fB, 2024). With Prolia\u2019s core patent expiring in 2025<\/strong> and Xgeva\u2019s in 2027<\/strong>, biosimilar entry is poised to capture 30\u201340%<\/strong> share within three years, driven by payer pressure and clinic\u2011level switching protocols. Boan\u2019s cost\u2011advantaged manufacturing in China positions BA6101\/BA1102 at a 30\u201350% discount<\/strong> to Amgen\u2019s WAC pricing.<\/p>\n\n\n\n

Strategic Implications<\/h2>\n\n\n\n